Comparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in man.
The bioavailability of 500 mg of a microsize formulation of griseofulvin has been compared to two new ultramicrosize griseofulvin formulations, two 165 mg tablets and a 330 mg tablet, in sixteen healthy, male, volunteers in a randomized crossover study design. Based on the griseofulvin plasma levels measured at specified times over a 48-hour period, the major bioavailability parameters (i.e., area under plasma concentration-time curve, maximum plasma concentration, and time to reach maximum plasma concentration) were determined and statistically evaluated. The results showed that one 330 mg ultramicrosize tablet is bioequivalent to two 165 mg ultramicrosize griseofulvin tablets and that either ultramicrosize griseofulvin dosage regimen is bioequivalent to 500 mg of the microsize griseofulvin formulation.
D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D006118:Griseofulvin / Q000097:blood*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate
D006118:Griseofulvin